| Literature DB >> 27113370 |
Philip Blumenfeld1, Neilayan Sen1, Ross Abrams1, Dian Wang2.
Abstract
Soft tissue sarcomas (STS) consist of a heterogeneous group of rare malignancies arising from mesenchymal origin. While surgical resection is the primary treatment for STS, the use of radiotherapy (RT) as an adjunctive modality has been shown to improve oncologic outcomes. Technologic improvements, such as image guidance and intensity-modulated radiotherapy that significantly improve both the precision and delivery of RT, have led to the reduction of long-term RT toxicities without compromising outcomes. This review addresses these technologic advancements as well as discussing the most current updates regarding the use of brachytherapy, charged particles, and novel agents with RT.Entities:
Keywords: IGRT; IMRT; Neoadjuvant radiotherapy; Radiation therapy; SBRT; Sarcoma; Targeted therapy
Mesh:
Year: 2016 PMID: 27113370 DOI: 10.1007/s11912-016-0523-z
Source DB: PubMed Journal: Curr Oncol Rep ISSN: 1523-3790 Impact factor: 5.075